Back to Search Start Over

High-dose tramadol conversion to buprenorphine-naloxone.

Authors :
Kirk JK
Boyd CT
Cassidy-Vu L
McRae LP
Strickland HE
Fagan EB
Source :
Journal of opioid management [J Opioid Manag] 2023 Mar-Apr; Vol. 19 (2), pp. 187-190.
Publication Year :
2023

Abstract

Buprenorphine-naloxone is a combination medication of an opioid partial agonist and opioid antagonist that is proven to be effective in outpatient management of opioid use disorder (OUD). Tramadol is a centrally acting analgesic. This commonly used pain medication inhibits serotonin and noradrenaline reuptake by acting as a selective agonist on opioid µ receptors. Transition and tapering high-dose tramadol to buprenorphine-naloxone is not well described in the literature. We report a case of a patient who was taking 1,000-1,250 mg of tramadol daily upon presentation to the clinic. She was originally prescribed 150 mg daily with escalation in dose and frequency over a 10-year period. The patient was converted to bupren-orphine-naloxone and has been successful in treatment of OUD for 1 year.

Details

Language :
English
ISSN :
1551-7489
Volume :
19
Issue :
2
Database :
MEDLINE
Journal :
Journal of opioid management
Publication Type :
Academic Journal
Accession number :
37270427
Full Text :
https://doi.org/10.5055/jom.2023.0774